20-F: XTL Biopharmaceuticals Shifts Focus to Psychedelics

XTL Biopharmaceuticals Ltd. has filed its annual report on Form 20-F, detailing its financial performance and strategic shifts, including the acquisition of Psyga Bio Ltd. and the ongoing challenges with The Social Proxy Ltd.

Summary

• XTL Biopharmaceuticals Ltd. has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025.
• The company has undergone significant strategic changes, including the acquisition of Psyga Bio Ltd., a biotechnology company focused on psychedelic and functional mushroom-derived products.
• XTL Biopharmaceuticals has also experienced difficulties with its subsidiary, The Social Proxy Ltd., which has entered liquidation proceedings.
• The company's financial statements indicate a net loss of $6,969 thousand for the year ended December 31, 2025, with an accumulated deficit of $165,632 thousand.
• XTL Biopharmaceuticals is actively seeking additional financing to continue its operations and pursue its business plan.
• The company is facing continued scrutiny from Nasdaq regarding its listing compliance, with ongoing efforts to meet requirements following a potential delisting notice.
• The company's primary focus has shifted from its previous biopharmaceutical activities to the development of psychedelic therapeutics through its subsidiary, Psyga Bio Ltd.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's severe financial distress, going concern issues, and Nasdaq delisting concerns, despite the strategic pivot to the promising psychedelic sector.

Positives

• Acquisition of Psyga Bio Ltd. positions the company in the growing psychedelic therapeutics market.
• Psyga Bio Ltd. operates a licensed, GMP-ready pharmaceutical manufacturing facility.
• Psyga Bio Ltd. has a pipeline of seven approved Phase 2a human clinical trials.
• The company has a strategy to identify and acquire high-potential intellectual property and technology assets.

Negatives

• The company incurred a net loss of $6,969 thousand for the year ended December 31, 2025.
• The company has an accumulated deficit of $165,632 thousand as of December 31, 2025.
• The company has substantial doubt about its ability to continue as a going concern.
• The Social Proxy Ltd., a former subsidiary, has entered liquidation proceedings.
• The company received a delisting notice from Nasdaq due to not meeting continued listing requirements, although it is appealing and working towards compliance.
• The company has minimal cash and cash equivalents ($76 thousand as of December 31, 2025), highlighting a significant need for financing.
• The company has no revenues and no cost of service or sales and marketing expenses from continuing operations.

Risks

• Substantial doubt about the company's ability to continue as a going concern.
• Raising additional capital may cause dilution to existing stockholders.
• The company's business, financial condition, and results of operations may be materially adversely affected by geopolitical instability.
• The company may fail to realize the anticipated benefits of its acquisition of Psyga Bio Ltd.
• The acquisition of Psyga Bio Ltd. subjects the company to entirely new risks and uncertainties in the psychedelic therapeutics industry.
• Psygas product candidates are in early stages of development and may never receive regulatory approval or become commercially viable.
• The FDA regulatory pathway for psychedelic compounds is complex, evolving, and uncertain.
• Clinical trials of psychedelic compounds face unique methodological challenges.
• The company may fail to regain compliance with Nasdaq continued listing requirements, leading to delisting.
• The company's operations in Israel are subject to political, economic, and military instability.
• The company's financial condition and results of operations could be adversely affected by inflation and foreign currency fluctuations.
• The company has identified a material weakness in its internal accounting and financial reporting controls.

Future Outlook

The company anticipates continued losses and negative cash flows from operating activities for the foreseeable future. Its strategy relies on external growth through mergers and acquisitions, which is capital-intensive and dependent on securing additional financing. The company's ability to continue as a going concern is contingent upon successfully raising sufficient funds to sustain operations and execute its growth strategy.

Management Comments

• Management has concluded that there is substantial doubt about our ability to continue as a going concern which could prevent us from obtaining new financing on reasonable terms or at all.
• We expect to continue to incur losses for the foreseeable future, and we may never achieve or maintain profitability.
• Our business, financial condition and results of operations may be materially adversely affected by any negative impact on the global economy and capital markets resulting from the conflict in Ukraine, Iran or any other geopolitical tensions.

Industry Context

StockSavvy.ai notes that XTL Biopharmaceuticals' strategic shift into the psychedelic therapeutics sector aligns with a broader industry trend of exploring novel treatments for mental health and neurological conditions. The company's acquisition of Psyga Bio Ltd. positions it within this emerging and highly scrutinized market, which faces significant regulatory hurdles and evolving public perception.

Comparison to Industry Standards

• XTL Biopharmaceuticals' financial performance, characterized by significant net losses and an accumulated deficit, is not uncommon for early-stage biotechnology companies, particularly those in the nascent psychedelic therapeutics sector.
• However, the company's minimal cash reserves ($76 thousand) and the substantial doubt about its ability to continue as a going concern place it in a precarious financial position compared to more established players in the industry.
• Competitors like COMPASS Pathways and MindMed are further along in their clinical development and regulatory processes, indicating a more advanced stage of industry maturation for those companies.

Corporate Governance

Legal Proceedings

• The company is a party to a legal proceeding in the Magistrate Court in Tel Aviv-Jaffa concerning allegedly unpaid legal fees for services rendered in connection with the acquisition of The Social Proxy. The company contests the claim.

Related Party Transactions

• A convertible loan of approximately $208 thousand was received from a director in 2025, bearing interest at 8% and convertible into ADSs at a 20% discount.
• The company paid fees to an accounting firm where the CFO is a partner for controller and bookkeeping services.
• The company's investment in InterCure Ltd. was considered a related party transaction until its disposal in 2025.

Stakeholder Impact

• Shareholders face significant risk of dilution due to potential future equity issuances and the company's going concern issues.
• The potential delisting from Nasdaq could make it more difficult for investors to sell their shares and could negatively impact the stock price.
• Creditors may be concerned about the company's ability to meet its obligations given its financial condition.

Next Steps

• Secure additional financing to meet operational needs and pursue growth strategy.
• Demonstrate compliance with Nasdaq continued listing requirements by June 30, 2026.
• Integrate Psyga Bio Ltd. operations and advance its clinical pipeline.
• Continue to monitor and manage cybersecurity risks.

Key Dates

Recommendation

Given the severe financial distress, going concern issues, Nasdaq delisting risks, and the material weakness in internal controls, the company presents a high-risk investment. While the pivot to psychedelics is strategically sound, the immediate operational and financial challenges outweigh the potential long-term benefits for most investors at this juncture.

Keywords

XTL Biopharmaceuticals, Form 20-F, Psyga Bio, Biotechnology, Psychedelic Therapeutics, SEC Filing, Annual Report, Going Concern, Nasdaq Listing, The Social Proxy